Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.19.1
Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 08, 2019
Jan. 14, 2019
Nov. 15, 2018
Sep. 29, 2014
Jan. 07, 2013
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Sep. 24, 2014
Royalty expenses           $ 31,284 $ 31,689    
ChubeWorkx [Member]                  
Royalty expenses           15,642      
Thorofare Lease [Member]                  
Operating lease with annual rentals including common area maintenance           132,000      
Lease agreement, extended term         7 years        
Lease agreement, expiration date         Dec. 31, 2019        
Rent expense           41,365 42,218    
Pitman Lease [Member]                  
Operating lease with annual rentals including common area maintenance           40,839      
Rent expense       $ 6,156   $ 10,210 $ 9,913    
Lease, term of agreement           29 months     60 months
Lease agreement, term description           The lease took effect on August 1, 2017 and runs through December 31, 2019.      
Security deposit               $ 4,950  
Settlement Agreement [Member]                  
Settlement agreed amount $ 2,250,000                
Insurance coverage amount               500,000  
Loss Contingency, Damages Sought, Value               $ 500,000  
Settlement Agreement [Member] | Watts Action [Member]                  
Payment of attorney' fees   $ 200,000              
Settlement Agreement [Member] | ChubeWorkx [Member]                  
Percentage of royalty received           5.00%      
Percentage of royalty retain           50.00%      
Due to related parties owned           $ 549,609      
Settlement Agreement [Member] | ChubeWorkx [Member] | Royalty [Member]                  
Royalty revenue           $ 5,000,000      
Marketing Contract [Member]                  
Allegations, description     On November 15, 2018, Typenex Medical LLC ("Typenex"), a telemarketing entity with whom the Company had entered into a marketing and commission agreement dated September 30, 2016 (the "Marketing Contract"), filed an arbitration against the Company before JAMS ADR (the "Arbitration"), and an arbiter was appointed to the Arbitration on December 14, 2018. In the Arbitration, Typenex has stated that it seeks "at least" $220,500 based on the allegation that the Marketing Contract entitles Typenex to a commission on sales of certain of the Company's heparin-related products in the period two years from the Marketing Contract's expiration            
Marketing Contract [Member] | Minimum [Member]                  
Loss Contingency, Damages Sought, Value     $ 220,500